Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Wayfair Inc (W) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs Wayfair Inc — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while Wayfair Inc trades at $104.22 (market cap $14.79B). The key difference: Wayfair Inc is far larger — about 3× Travere Therapeutics Inc. Common Stock's market cap, and Wayfair Inc is trading nearer its 52-week high, Travere Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and Wayfair Inc for 8 Days on average.
| TVTX | W | |
|---|---|---|
Market Cap | $4.88B | $14.79B |
Volume | 1,668,577 | 1,870,669 |
Sector | Health | Consumer Cyclical |
52-Week High | $67.52 | $119.05 |
52-Week Low | $26.79 | $57.40 |
Typical Hold Time | 0 Days | 8 Days |
Enterprise Value | $5.01B | $17.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Wayfair (W) trades at $107.99, up 1.74% on the day, with a bullish technical signal from moving averages. The company reported revenue of $12.46B in 2025 but a net loss of $313M, with a negative net income margin of -2.49%. Analyst consensus is positive with a $114.13 price target, and recent news highlights brand expansion and upcoming Q3 2026 earnings.
The outlook for Wayfair hinges on improving profitability amid competitive pressures. While revenue growth is steady, persistent losses and high debt-to-asset ratio of 95.11% pose risks. The stock offers upside to the consensus target but requires monitoring of cost management and consumer spending trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About Wayfair Inc
Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →
